BFIM
VRTX icon

Beese Fulmer Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Beese Fulmer Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25
Closed -$7K – 537
2020
Q2 		$7K Buy
+25
New +$6.78K ﹤0.01% 513

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Beese Fulmer Investment Management's VRTX Position: Q3 2020 in Review

Beese Fulmer Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2020, closing a stake of 25 shares — an estimated $7K sold.

Beese Fulmer Investment Management first reported a position in VRTX in Q2 2020 and held it in 1 quarter. The position peaked at $7K in Q2 2020. 951 funds tracked by Wall St. Rank hold VRTX as of Q3 2020.

  • Beese Fulmer Investment Management reported no remaining Vertex Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Beese Fulmer Investment Management sold 25 Vertex Pharmaceuticals shares in Q3 2020, an estimated $7K.
  • Beese Fulmer Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Beese Fulmer Investment Management's Vertex Pharmaceuticals position peaked at $7K in Q2 2020.
  • 951 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2020.

Based on Beese Fulmer Investment Management's 13F filing for Q3 2020, filed 8 Oct 2020.